

Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours

Friday, April 29, 2022



Vaccinate ALL 58

Together we can end the pandemic.

Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
<https://eziz.org/covid/education/>



If you have technical difficulties, please contact Rachel.Jacobs@cdph.ca.gov

Agenda: Friday, April 29, 2022

No.	Item	Speaker	Time (AM)
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 – 9:05
2	Clinical Update	Caterina Liu, M.D. (CDPH)	9:05 – 9:25
3	Vaccine Administration	Elizabeth Reosti (CDPH)	9:25 – 9:30
		Q&A	9:30 – 9:35
4	Storage & Handling	Alan Hendrickson (CDPH)	9:35 – 9:40
5	Vaccine Management	Eric Norton (My Turn) and Claudia Aguiluz (CDPH)	9:40 – 9:50
6	Wrap Up & Resources	Leslie Amani (Moderator)	9:50 – 10:00
		Q&A	

Announcements

Leslie Amani, CDPH

CDPH COVID-19 Policy Alerts



CDPH COVID-19 Policy Alerts Registration

Sign up to receive alerts for updates to California state public health officer orders and public health mandates related to COVID-19.

First Name*

Last name *

Email *

County*

Sign up to receive alerts for updates to California state public health officer orders and public health mandates related to COVID-19.

Today: Billing and Reimbursement Webinar

CDPH is hosting a Billing and Reimbursement webinar. Please register to hear information and updates from Dr. Robert Schechter, CDPH, Dr. Hisham Rana and Cindy Garrett from the Department of Healthcare Services, and Mark Lane from the California Medical Association.

When: Friday, April 29, 2022

Time: 12:30PM-1:30PM

[Register here!](#)



Upcoming: Planning for Under 5 Vaccinations

Please join CDPH for a Planning for Under 5 Vaccinations Webinar. Content will include current information about Under 5 COVID-19 vaccines, clinical updates, storage & handling, and job aids, resources and trainings.

May 9, 2PM-3PM [Register here!](#)

May 10, 5:30PM-6:30PM [Register here!](#)



Pfizer COVID-19 Vaccine Medical Updates & Training Sessions



Date & Time (linked)	Password
Tuesday, May 3 - 12PM	3pX6j2tR2YW
Wednesday, May 4 - 9AM	pGvsnAJS396
Thursday, May 5 - 9AM	Ez7QbmGs5T7
Tuesday, May 10 - 12PM	2smGP2QX9pB
More sessions listed! NOTE: All times listed here are PDT.	

For providers and immunization staff personnel. **Please attend one of these sessions!**

Updated Session Format!

- Medical updates, including recent updates to the CDC Interim Clinical Considerations
- Overview of healthcare provider resources
- Storage, handling, and administration for:
 - Ages 5 through 11 Years
 - Ages 12 Years and Older

Stay informed! Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

Vaccinate ALL 58 California COVID-19 Vaccination Program ENHANCED BY Google

Program Updates

- Program Enrollment
- My Turn Onboarding
- Vaccine Management
- Vaccine Administration
- Reporting Requirements
- Archived Communications
- Patient Resources

Updates for Providers

- FAQs
- Provider Office Hours
- myCAvax Training
- Training Calendar

Alerts:

Medi-Cal News Flash

- FQHC, RHC and Tribal FQHC Providers May Now Submit Claims for COVID-19 Vaccine Administration

Updated Vaccination Schedule

- Interim Clinical Considerations Updated for 2nd Booster March 31
- COVID-19 Vaccine Timing by Age (Eligibility Chart)
Spanish: Calendario de la Vacuna COVID-19 por Edad (Tabla de Elegibilidad)
- COVID-19 Vaccine Timing for 2nd Dose
- COVID-19, Myocarditis, and Vaccines Fact Sheet

Vaccine Expiration

- Janssen (Johnson & Johnson) Expiration Extension
- March & April COVID-19 Vaccine Expiration Dates

Now Enrolling Providers of Pediatric Services

- Infographic: MAKE NO MISTAKE--COVID-19 Is A Childhood Illness
- Benefits for Primary Care Providers
- Find Information on How to Enroll
- Mis-Disinformation "6 Myths" Provider Poster
- Welcome VFC Providers | Flyer | VFC vs. COVID Programs

Other New Resources

- Recommending COVID-19 Vaccination: Clinical Talking Points for Providers of Pediatric Services
- Requesting COVID-19 Vaccination Staff

Provider Support

COVID Call Center

Email: [Program Info](#)
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

myCAvax and My Turn

Email:
[myCAvax Technical Support](#)
[MyTurn Onboarding](#),
[MyTurn Technical Support](#)
Phone: (833) 502-1245
Mon-Fri, 7AM-7PM
Sat-Sun, 8AM-1PM

My Turn Clinic Translation Line:
(833) 980-3933
Mon-Fri: 8AM-8PM
Sun-Sat: 8AM-5PM

Vaccines

[Manufacturer Contacts](#)

Featured Resources

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 04/28/2022
- Currently in its 69th iteration!

 Updated **Q: What are the major reporting requirements for COVID-19 Vaccine Providers?**

A: Starting May 1, 2022, [VaccineFinder](#) reporting requirements will change from [daily to weekly](#), by close of business Fridays. All other reporting requirements remain the same. Within **24 hours of administering** a dose of COVID-19 vaccine, Providers must report COVID-19 [doses administered](#) to the local immunization registry (e.g., CAIR2, Healthy Futures, or SDIR) and submit [race and ethnicity](#) for every vaccinated patient.

 Updated **Q: Given the reporting functionality in myCAvax, do I have to report my weekly on-hand inventory in VaccineFinder?**

A: Yes, it is a federal requirement that California COVID-19 vaccine Providers continue to report weekly on-hand inventory in VaccineFinder.

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

New and Updated FAQs.....	2
Pediatric Providers.....	2
Vaccine Program Management.....	3
Provider Enrollment.....	4
Ordering.....	4
Distribution/Redistribution.....	5
Vaccine Administration.....	5
Additional/Booster Doses.....	7
Vaccine Storage & Handling.....	9
Inventory.....	11
Reporting.....	11
Billing & Reimbursement.....	12
Communication Resources.....	13

[Provider FAQs on EZIZ, Updated Weekly](#)



COVID-19 Vaccination Program Webinars and Training for Providers

Week of May 2, 2022

Note: Calendar subject to change

	Monday 5/2	Tuesday 5/3	Wednesday 5/4	Thursday 5/5	Friday 5/6
myCAvax		What's New in myCAvax 12:30 pm – 1:00 pm			Provider Office Hours 9:00 am – 10:00 am
Combined Office Hours and Events	My Turn and myCAvax Office Hours 12:00 pm – 1:00 pm	Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: 3pX6j2tR2YW	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: pGvsnAJS396	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: Ez7QbmGs5T7	
				Crucial COVID-19 Conversations Webinar: Talking with Patients about COVID-19 Vaccines: Back to the Basics 12:00 pm – 1:00 pm	

* Pfizer BioNTech COVID-19 Vaccine Training & Education topics vary by day and include the latest information about vaccine storage, handling, preparation, and administration; recent medical updates, healthcare provider resources, and a Q&A session

View On Demand			
	<ul style="list-style-type: none"> Intro to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (*Requires My Turn Login) 	<ul style="list-style-type: none"> Latest Features in myCAvax for Providers (*Requires myCAvax Login) myCAvax Release Notes for LHJs and CDPH Users (*Requires myCAvax Login) Crucial COVID-19 Conversations Archived Webinars and Slides NEW! 	<ul style="list-style-type: none"> Provider 101 Account Enrollment: Section A: Organization Application (v. 10/21/21) Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21) Provider Office Hours and MCE Office Hours Archived Sessions

Help

Website: www.eziz.org/covid, [FAQs](#)
 General email: covidcallcenter@cdph.ca.gov
 CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov
 myCAvax Help Desk Email: myCAvax.HD@accenture.com
 Phone: (833) 502-1245



Last updated: 4/28/22

Clinical Update

Caterina Liu, M.D., CDPH


COVID-19 Vaccine Products Possibly up for Review by the FDA in the Coming Months

Vaccine Brand	Regulatory Request	Dose	Review status
Pfizer	Full licensure for primary series, adolescents 12-15 years	30ug	<u>Submitted, 12/16/21</u>
	NEW EUA for booster dose, children 5-11 years	10ug	<u>Submitted, 4/26/22</u>
	EUA for children 6 months to <5 years	3ug	<i>Not yet submitted</i>
Moderna	NEW EUA for primary series, children 6 months to <6 years	25ug	<u>Submitted, 4/28/22</u>
	EUA for primary series, children 6-11 years	50ug	<u>Submitted, 3/23/22</u>
	EUA for primary series, adolescents 12-17 years	100ug	<u>Submitted, 6/10/21;</u> <i>updated submission pending</i>
Novavax	EUA for adults 18+		<u>Submitted, 1/31/22</u>

Subject to change: stay tuned for updates

CDC Booster Effectiveness Data

Summary: VE of 2 doses of mRNA vaccine increases with increasing severity of outcome during Omicron in adults ≥18 years; 3rd dose increases VE



Booster receipt increases protection across all outcomes.
Booster dose VE remains high among immunocompetent individuals 4-6 months after dose.

*Among immunocompetent individuals ≥65 years of age.

- COVID-19 vaccines are highly effective against severe disease from the Omicron variant
- First booster provides added protection against infection and severe disease.
- Protection against severe disease is more durable than protection against infection.
- **A first booster is an important tool to prevent severe disease**

Summary: VE during Omicron

	Children 5-11 years	Adolescents, 12-17 years	Adults ≥18 years
2-dose VE against:			
Infection (+/- symptoms)	Limited protection	Limited protection	Limited protection
ED/UC	Higher protection	Higher protection	Higher protection, some waning
Hospitalization	Highest protection, not enough cases to estimate waning	Highest protection, some waning	Highest protection, some waning
3-dose VE against:			
Infection (+/- symptoms)	N/A	Too early to assess	Substantial additional protection for all outcomes; limited waning for hospitalization, especially among immunocompetent
ED/UC			
Hospitalization			

Protection from death: Small numbers of deaths make estimation difficult, but consistently lower rates among vaccinated compared to unvaccinated during Omicron suggest that vaccines protect against deaths in all age groups

COVID-19 Vaccine Safety Technical (VaST) Work Group

VaST assessment

COVID-19 vaccine first booster dose safety data to inform second dose booster vaccination

- VaST has provided assessments on booster dose safety at 4 ACIP meetings
- Today's assessment included data from VSD as well as v-safe, VAERS, VA
- Reactogenicity is similar to or lower than that seen after the primary series
- Myocarditis risk appears lower than after a primary series dose 2
- Further work and analyses are needed to understand pericarditis risk
- While data do not suggest safety concerns beyond those previously identified, VaST will carefully monitor data on myocarditis and pericarditis after booster doses

Second Booster Benefits Against Severe Disease

Benefits after mRNA COVID-19 booster dose among persons ages ≥50 years


Scenario:

- 55% VE for primary series¹
- Boost to 88% VE for single booster¹
- Assumed boost to 95% VE for second booster²

For every million series completed

Vaccine series	VE for hospitalization
Primary series	55%
Primary series + booster dose	88%
Primary series + second booster dose	95%

COVID-19-Associated Hospitalizations, ICU Admissions, Deaths Prevented per Million Series Completed



VE: Vaccine Effectiveness; ¹ VE estimate from IVY and VISION: <https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness>; ² Relative VE estimate for 4th dose: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2201688?articleTools=true>; COVID-NET hospitalization rates from the week of February 26, 2022

- CDC modeling study
- Second booster additional benefit estimated from studies in people 60+ in Israel
- Added magnitude of benefit of second booster dose is less than the added benefit of first booster dose or primary series.
- **Second booster dose prevents additional severe outcomes.**

Summary

Benefits and Harms

- **Data from Israel demonstrate increased immune response after fourth dose**
 - Higher rates of infection and severe illness seen in 3-dose recipients compared to 4-dose recipients
- **Greatest benefit from vaccination is achieved from receipt of primary series and first booster dose**
 - Additional benefits may be achieved through receipt of a second booster dose
- **Known and possible benefits outweigh risks (including theoretical risks)**
 - Individual factors that influence magnitude of benefits for second booster
 - Monitor additional data to inform theoretical risks

Updated CDC Guidance for COVID-19 Vaccine Booster for People with Prior or Current SARS-CoV-2 Infection

People with known current SARS-CoV-2 infection should defer any COVID-19 vaccination, including booster vaccination, at least until recovery from the acute illness (if symptoms were present) and [criteria](#) to discontinue isolation have been met.

In addition, people who recently had SARS-CoV-2 infection may consider **delaying their first or second COVID-19 vaccine booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic)**. [Studies](#)  have shown that increased time between infection and vaccination may result in an improved immune response to vaccination. Also, a low risk of reinfection has been observed in the weeks to months following infection. Individual factors such as risk of COVID-19 [severe disease](#), [COVID-19 community level](#), or characteristics of the predominant SARS-CoV-2 strain should be taken into account when determining whether to delay getting a booster dose after infection.

[Viral testing](#) to assess for acute SARS-CoV-2 infection or [serologic testing](#) to assess for prior infection is not recommended for the purpose of vaccine decision-making.

Updated CDC Considerations for COVID-19 Vaccine 2nd Booster

Eligible People Who May Consider Getting the 2nd Booster Dose As Soon As Possible

-  People with certain underlying medical conditions that increase the risk of severe COVID-19 illness
-  People who are moderately or severely immunocompromised
-  People who live with someone who is immunocompromised, at increased risk for severe disease, or who cannot be vaccinated due to age or contraindication
-  People at increased risk of exposure to SARS-CoV-2, such as through occupational, institutional, or other activities (e.g., travel or large gatherings)
-  People living or working in an area where the COVID-19 community level is medium or high

Updated CDC Considerations for COVID-19 Vaccine 2nd Booster

Eligible People Who May Consider Waiting to Receive a 2nd Booster Dose

-  People with recent SARS-CoV-2 infection within the past 3 months
-  People who may be hesitant about getting another recommended booster dose in the future, as a booster dose may be more important in the fall and/or if a variant-specific vaccine is needed.

CDC 2nd Booster Flyers

Clinical Guidance



Clinical Considerations Second COVID-19 Vaccine Booster Dose

Everyone ages 12 years and older **should** get a booster when they are eligible. Some people **may** get a 2nd booster dose.

When you discuss a 2nd COVID-19 vaccine booster dose with patients:

Who is eligible: 	<ul style="list-style-type: none"> - People 50 years of age and older, regardless of health status - People 12 years of age and older who are moderately or severely immunocompromised - People 18 years of age and older who received 2 doses of Janssen vaccine
Who might consider getting the 2nd booster dose now: 	<p>Among people who meet the criteria for eligibility (listed above; "who is eligible"), clinical considerations for getting the dose now include:</p> <ul style="list-style-type: none"> - People with underlying medical conditions that increase the risk of severe COVID-19 disease - Providers caring for people who are moderately or severely immunocompromised may take into consideration the patient's degree of immunosuppression as well as timing (e.g., initiation or resumption of immunosuppressive therapies) - People who are moderately or severely immunocompromised - People who live with someone who is immunocompromised, at increased risk for severe disease, or who cannot be vaccinated due to age or contraindication - People at increased risk of exposure to SARS-CoV-2, such as through occupational, institutional, or other activities (e.g., travel or large gatherings) - People who live or work in or near an area where the COVID-19 community level is medium or high or are traveling to such an area
Who might consider waiting to receive a 2nd booster dose: 	<p>Among people who meet the criteria for eligibility (listed above; "who is eligible"), clinical considerations for getting the dose now include:</p> <ul style="list-style-type: none"> - People who have had a SARS-CoV-2 infection within the last 3 months - People who may be hesitant about getting another recommended booster dose in the future, as a booster dose may be more important in the fall and/or if a variant-specific vaccine is needed
If you vaccinate: 	<ul style="list-style-type: none"> - Separate the 2nd booster dose from the previous dose by at least 4 months. - Only Moderna or Pfizer-BioNTech COVID-19 vaccine products can be administered for the 2nd booster dose. - Age indications and dosage (amount injected) vary by product. - Pfizer-BioNTech COVID-19 Vaccine booster dose: Can be administered to people ages 12 years and older. The correct dosage is 0.3 mL. - Moderna COVID-19 Vaccine booster dose can be administered to people ages 18 years and older. The correct dosage is 0.25 mL.

CDC References and Resources:
 COVID-19 by County www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html
 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
 Interim COVID-19 Immunization Schedule for Ages 5 Years and Older: www.cdc.gov/vaccines/covid-19/downloads/covid-19-immunization-schedule-ages-5yrs-older.pdf
 People with Certain Medical Conditions: www.cdc.gov/coronavirus/2019-ncov/health-care/precautions/people-with-medical-conditions.html
 U.S. COVID-19 Vaccine Product Information: www.cdc.gov/vaccines/covid-19/info-by-product/index.html



CS201024-A 04/01/2022

Public Information



Thinking About Getting a Second COVID-19 Vaccine Booster Dose

In March 2022, CDC updated its COVID-19 vaccination guidance to say that certain groups of people may get second boosters. If you're in one of those groups, it's up to you whether or not to get a second booster right now, based on the benefits and risks the vaccine may provide to you. Your healthcare provider can help you review your options. Here are factors to think about as you consider a second booster.

1. Are you eligible?	<p>Right now, you're eligible for a 2nd COVID-19 booster if you're:</p> <ul style="list-style-type: none"> - 50 years of age and older and received an initial booster at least 4 months ago. - 12 years of age and older and moderately or severely immunocompromised and received an initial booster at least 4 months ago - Received 2 doses of Janssen vaccine at least 4 months ago
2. Are you (or is someone you live with) more likely to get very sick?	<p>Certain factors can make it more likely someone will get very sick from COVID-19. It may be helpful to get a second booster now if you are (or if someone you live with is):</p> <ul style="list-style-type: none"> - Moderately or severely immunocompromised - More likely to get very sick from COVID-19 - More likely to be exposed to COVID-19 through your job, where you live, or other factors (such as frequent travel or large gatherings) - In an area with medium to high COVID-19 community levels - Or if someone you live with is unvaccinated.
3. Can you wait?	<p>You may consider waiting to get a second booster if you:</p> <ul style="list-style-type: none"> - Had COVID-19 within the past 3 months - Feel that getting a second booster now would make you not want to get another booster in the future (a second booster may be more important in fall of 2022, or if a new vaccine for a future COVID-19 variant becomes available).
If you get a second booster:	<ul style="list-style-type: none"> - Make sure it's been at least 4 months since your last COVID-19 booster. - Remember that second boosters can only be Moderna or Pfizer-BioNTech (and for 12-17 year-olds, only Pfizer-BioNTech). - You can self-attest that you have a moderately or severely weakened immune system. This means you do not need any documentation that you have a weakened immune system to receive COVID-19 vaccines (including boosters) wherever they're offered.

CDC References and Resources:
 COVID-19 by County www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html
 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
 Interim COVID-19 Immunization Schedule for Ages 5 Years and Older: www.cdc.gov/vaccines/covid-19/downloads/covid-19-immunization-schedule-ages-5yrs-older.pdf
 People with Certain Medical Conditions: www.cdc.gov/coronavirus/2019-ncov/health-care/precautions/people-with-medical-conditions.html
 U.S. COVID-19 Vaccine Product Information: www.cdc.gov/vaccines/covid-19/info-by-product/index.html



CS201024-A 04/01/2022

HHS 2nd Booster Materials

WE CAN DO THIS

Partner up with your organization's logo

Give Your COVID-19 Vaccination Protection a Boost

Booster shots are now available for everyone 12+ and vaccinated

COVID-19 vaccines continue to work very well at preventing severe illness, hospitalization, and death. A booster shot is an extra dose that helps keep up your protection.

When to get your booster
Get your 1st booster as soon as you're eligible:

- 5 months after your 2nd dose of the Pfizer-BioNTech or Moderna vaccine.
- 2 months after your single dose of the Johnson & Johnson vaccine.

You can get a 2nd booster 4 months after your 1st, if you're:

- 50+ and got the Pfizer or Moderna vaccine.
- 18+ and got the Johnson & Johnson vaccine.

Find free vaccines near you

- Visit [vaccines.gov](https://www.vaccines.gov)
- Text your ZIP code to 438829
- Call 1-800-232-0233
- Scan the QR code



© 2022 HHS. All rights reserved. April 7, 2022

PROTECT YOUR STAFF AND RESIDENTS WITH COVID-19 BOOSTERS

WE CAN DO THIS

Boosters help keep up protection. If you're 12+, you should get your 1st booster:

- 5 months after your 2nd dose of Pfizer or Moderna.
- 2 months after your single dose of Johnson & Johnson.

You can get a 2nd booster 4 months after your 1st, if you're:

- 50+ and got the Pfizer or Moderna vaccine.
- 18+ and got the Johnson & Johnson vaccine.

To schedule a vaccination clinic at your facility or nearby, reach out to your vaccine provider. If you need support:

- Contact your state or local health department.
- Call CDC INFO at 800-232-4636 to be matched with a vaccine provider for an on-site clinic.

Visit cdc.gov/coronavirus for more information on boosters.

PROTECT YOUR LOVED ONES BY GETTING YOUR COVID VACCINE BOOSTERS

WE CAN DO THIS

Older adults are at high risk for severe illness from COVID.

Boosters help keep up protection for you and your loved ones. If you're 12+, you should get your 1st booster:

- 5 months after your 2nd dose of Pfizer or Moderna.
- 2 months after your single dose of Johnson & Johnson.

You can get a 2nd booster 4 months after your 1st, if you're:

- 50+ and got the Pfizer or Moderna vaccine.
- 18+ and got the Johnson & Johnson vaccine.

Visit cdc.gov/coronavirus for more information on boosters.

FAQs: CDPH 2nd Booster

- Summarizes eligibility, clinical guidance, and benefits/risk of second boosters
- Useful tool to share with residents, staff and other partners

SECOND COVID-19 BOOSTER DOSE FAQS FOR LONG-TERM CARE SETTINGS

ELIGIBILITY

- 1. Who is eligible for a second booster?**
 - o People 50+ years old
 - o People 12+ years old who are [moderately or severely immunocompromised](#) (e.g., organ transplant, on chemotherapy, or other conditions)
 - o People 18-49 years old who got two doses of J&J vaccine
 - o There is no current guidance for a second booster for healthcare workers or long-term care facility (LTCF) residents who don't meet the age or clinical criteria.
- 2. When should they get a second booster?**
 - o At least 4 months after their first booster.
- 3. What if they recently caught COVID-19?**
 - o People can get a booster after infection as soon as they feel better, are fever-free and no longer need to isolate. However, people who had COVID-19 within the last 3 months may consider waiting to get their second booster.
- 4. Which vaccine may they get for a second booster?**
 - o People 18+ years old may get Pfizer or Moderna mRNA COVID-19 vaccine.
 - o People 12-17 years old may only receive the Pfizer vaccine.
- 5. Who might benefit most from getting a second booster now?**
 - o People who are [immunocompromised](#)
 - o People with [medical conditions](#) that increase their risk of getting very sick from COVID-19 (e.g., people with heart, lung, or kidney disease; diabetes; or dementia).
 - o People who live with someone who is immunocompromised, at higher risk for severe disease, or can't be vaccinated due to age or other reasons.
 - o People who are at higher risk of exposure to COVID-19 (e.g., live or work in a LTCF or in a community where the COVID-19 level is high).

Second COVID-19 Booster Dose FAQs

April 2022

BENEFITS AND RISKS

6. What are the benefits of a second booster?

- o Protection from the first booster may decrease over time. A second booster helps sustain protection against COVID-19 infection and severe disease.
- o LTCF residents and staff who are 50+ years or immunocompromised are at high risk of getting very sick from COVID-19 and may especially benefit from a second booster.
- o The initial series of doses and first booster provide strong protection against COVID-19 and should be offered to those who have not yet received these doses.

7. What are the risks of a second booster?

- o COVID-19 vaccines are safe. Over 600,000 people 60+ years in Israel received a second booster dose of the Pfizer vaccine, with no new safety concerns.

ADDITIONAL INFORMATION

8. Are second boosters required?

- a. There is no current requirement for a second booster for LTCF residents or staff.
- b. A second booster is not currently required by CDC to be classified as up to date with COVID-19 vaccination.

9. How should LTCFs utilize second booster doses?

- o Half of California LTCF residents received their first booster by mid-December 2021 and so [will be eligible for a second booster in April 2022](#).
- o LTCFs should inform eligible residents and staff about the new recommendations and how to access a second booster ([MyTurn, Vaccines.gov](#)).
- o LTCFs may choose to offer second boosters to eligible residents and staff now.
- o LTCFs should develop a plan for offering residents additional booster doses in the future if there are additional surges or a newer vaccine is needed. For additional details on COVID vaccine access, refer to the [LTCF COVID-19 Vaccine Toolkit](#).

RESOURCES

- o [CDC Interim Clinical Considerations for Use of COVID-19 Vaccines](#)
- o [FDA COVID-19 Update, 3/29/2022](#)
- o [WSSSRW Statement, 3/30/2022](#)

Second COVID-19 Booster Dose FAQs

2

April 2022

UPDATED

CDPH Booster Posters

IF YOU WORK IN A HEALTH CARE SETTING... **BOOST YOUR HEALTH WITH COVID-19 BOOSTER DOSES!**



PROTECT YOURSELF



You've worked so hard to help your patients. You owe it to yourself to prioritize your health by getting a booster. If you are 50 or older or immunocompromised, you can now get a second booster.

PROTECT YOUR FAMILY AND COWORKERS

With boosters, your chances of getting very sick from COVID-19 are much lower and you are less likely to spread COVID-19 to those around you. Boosters restore protection against COVID-19.

PROTECT YOUR PATIENTS

COVID-19 can be dangerous and deadly, especially for your vulnerable patients.



GETTING BOOSTERS IS ANOTHER EASY THING YOU CAN DO TO PROTECT THEM.

COVID-19 vaccines are safe with millions safely immunized. Maximize your protection against COVID-19 with boosters.

Get your COVID-19 booster dose at:

**BOOST YOUR HEALTH.
GET YOUR COVID-19 VACCINE BOOSTER TODAY.**

California Department of Public Health | Immunization Branch
IMM-1428 (4/22)



IN THESE TIMES, EVERYONE COULD USE A BOOST



**BOOST YOUR
PHYSICAL HEALTH**



**BOOST YOUR
SOCIAL HEALTH**



**BOOST YOUR PROTECTION
AGAINST COVID-19 NOW**

COVID-19 vaccines **work very well** at preventing severe illness, hospitalization, and death.

Booster shots are extra doses that help maximize your protection against COVID-19.

Adults who are 50 and older or immunocompromised can now get a **second booster** of the vaccines made by Pfizer or Moderna at least 4 months after the first booster of any COVID-19 vaccine. COVID-19 vaccines and boosters are **safe, effective, and free**.

DON'T WAIT, VACCINATE!

Three ways to find free vaccines near you

- ✓ Visit [vaccines.gov](https://www.vaccines.gov) to find a walk-up site.
- ✓ Book an appointment on [My Turn](https://myturn.ca.gov) (myturn.ca.gov) or call (833) 422-4255.
- ✓ Check with your doctor, nurse or local pharmacy.


**BOOST YOUR HEALTH.
GET YOUR COVID-19 VACCINE BOOSTER TODAY.**

California Department of Public Health | Immunization Branch
IMM-1416 (4/22)



2nd Booster Resources

- [2nd Booster Clinical Considerations](#) (CDC)
- [2nd Booster Flyer for Patients](#) (CDC)
- [2nd Booster FAQs for LTCFs](#) *NEW!*
- [Older Adults Booster Poster](#) *UPDATED!*
- [Healthcare Worker Booster Poster](#) *UPDATED!*
- [LTCF COVID Vaccine toolkit](#) *UPDATED!*
- [Resources about COVID-19 Boosters](#) (HHS)
- [COVID-19 Resources for Long-Term Care Facilities](#)




[Link Here](#)

Vaccine Administration Data

Elizabeth Reosti, CDPH


Vaccine Administration Summary

as of April 28, 2022



74,815,999


Total Doses Administered:




Trends in Vaccine Administration

as of April 25, 2022

Daily Doses Administered




Weekly Doses Administered (thousands)




Trends in Vaccine Administration

as of April 25, 2022

- Increase in demand/uptake among 50-64 and 65+ age groups



Weekly Doses by Age Group



Percent Change from Previous Week	March 13, 2022	March 20, 2022	March 27, 2022	April 3, 2022	April 10, 2022	April 17, 2022
5-11	-12%	-20%	-17%	-2%	-16%	-16%
12-17	-11%	-15%	-25%	+9%	-22%	-22%
18-49	-11%	-10%	-14%	-3%	-16%	-16%
50-64	-8%	+165%	+41%	+2%	-16%	-16%
65+	+4%	+503%	+70%	-6%	-20%	-20%


5-to-11-year-old Vaccination Trends

as of April 25, 2022

Weekly New 5-11 year-old Fully Vaccinated Recipients by VEM

VEM Quartile
 Q4
 Q3
 Q2
 Q1

- Persistently declining demand/uptake among all equity quartiles




	March 13, 2022	March 20, 2022	March 27, 2022	April 3, 2022	April 10, 2022	April 17, 2022
Percent Change from Previous Week		-10%	-20%	-20%	-9%	-13%
Q1		-9%	-21%	-23%	-6%	-15%
Q2		-9%	-21%	-19%	-11%	-14%
Q3		-11%	-24%	-15%	-13%	-16%
Q4		-12%	-15%	-23%	-4%	-6%

1st Booster Vaccination Rates

as of April 25, 2022


- Booster rates lower among Black and Latinx populations

Received Booster (among booster-eligible population)



Detailed Vaccination Progress (Public)

1 Select Measure




2 Select Race/Ethnicity



3 View Age + Race/Ethnicity

Vaccinated Status by Age and Race-Ethnicity



	5-11	12-17	18-49	50-64	65+	Total
Asian	64.2%	91.8%	>95%*	93.0%	85.7%	93.6%
Black	21.2%	47.6%	55.4%	70.9%	71.0%	57.6%
Latino	22.8%	55.9%	62.2%	71.5%	71.1%	59.3%
White	28.0%	56.1%	67.2%	72.1%	76.5%	67.1%
Total	34.4%	66.7%	78.0%	84.0%	84.0%	75.2%

Data: 4/21/2022 11:59PM | Posted: 4/22/2022

Data Summary

as of April 25, 2022

Latest Metrics

74.8 Million doses administered

360k doses administered in previous week (-18% pt change)

6,945 new 5-to-11-year-old recipients (-13% pt change)

System Updates

- Public Dashboard reporting now Tuesdays and Fridays
- 4th doses included in overall dose admin count, but not currently displayed in immunization status

Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.



Storage & Handling

Alan Hendrickson, CDPH

Pediatric Pfizer (6 months – 4 years, maroon cap)

- Coming soon – mid-June?
- Storage and handling:
 - 12 months at ULT (-90° to -60° C)
 - 10 weeks at refrigerated temperatures (2° to 8° C)
 - 12 hours prior to first puncture at room temperature (8° to 25° C)
 - 12 hours after first puncture at room temperature (8° to 25° C)
- Presentation
 - 10 doses per vial
 - Diluent required
- The label

What's in a label?

Applicable to the following cap colors:

MAROON
(Ages 6 months
thru 4)

Label Characteristics Maroon Cap Ages 6 months through 4 years




If authorized by the FDA, **Maroon Cap** vaccine vials and cartons you receive will be labeled as Pfizer-BioNTech COVID-19 Vaccine

Initial shipments of Maroon Cap vials and cartons will have the following label characteristics:

Maroon Cap vaccine requires dilution prior to use

*Maroon Cap vial labels and cartons may state that a vial should be discarded **6 hours** after the first dilution. Results from recent stability studies will supersede the current vial label and support discarding the vaccine after **12 hours** from the time of dilution



IMPORTANT INFORMATION

- The vial and carton labels may state **2 years to <5 years** of age or **6 months through 4 years of age**.
- Vials with labels that state for use in individuals **2 years to <5 years of age** can be used for individuals **6 months through 4 years of age**.

***Note:** Prior to preparation of the vaccine, please review the EUA Fact Sheet (if authorized by the FDA) as the timeframe for use post-dilution has been extended to **12 hours**

 **FOR TRAINING PURPOSES ONLY – THE VACCINE HAS NOT BEEN AUTHORIZED FOR USE IN INDIVIDUALS YOUNGER THAN 5 YEARS OF AGE**

Moderna Pediatric

- Moderna has submitted data to the FDA for an EUA application for children 6 months to under 6 years of age and children 6 years to under 12 years of age.
- Approval expected early to mid-June
- Nothing firm is known of the presentation(s)
- Storage and handling:
 - 9 months at frozen temperatures (-50° to -15°C)
 - 30 days at refrigerated storage (2° to 8° C)
 - 12 hours at room temperature after first puncture (2° to 25° C)

Moderna Shipper Returns

- Effective 4/29/22, providers will no longer receive UPS return labels for medium and large frozen shipping containers. UPS return labels will continue to be provided for small shipping containers, which represent more than 98% of all Moderna shipments, so that these containers may be returned and refurbished.
- Please dispose of any medium or large frozen shipping containers and packing materials as you would any other waste. Providers are encouraged to recycle the cardboard components of their medium and large frozen shipping containers through their local recycling program.

Shelf-Life Extensions & Shipping Incidents

- Shelf-life Extensions
- Multiple shelf-life extensions approved over the past month
 - Please update your Vaccine Marketplace entries
 - Shipping Incidents
- Please report your shipping incidents (see the link below)
 - Report the shipment incident in myCAvax
 - Contact the manufacturer (TPR, Pfizer or McKesson)
 - Record the case number and resolution in myCAvax
 - Report wastage if applicable
- SAGA Logger (Pfizer)

SAGA Digital Data Logger Issues

Quality Reporting

Once you open your shipper, press and hold the stop button on the logger for five seconds to stop temperature monitoring. A Quality Report should be provided via email within 1-3 hours. Do not use the vaccine within this shipper until you receive the quality report from Controlant advising on further use.

Manual Upload Instructions

If the temperature monitoring device is unable to connect with the cell network, please follow the steps below. These steps allow Points of Use (POUs) to ensure proper data connection through a manual data upload using your local internet network. The manual data process steps are the same for both Controlant 10.01 and/or Controlant SAGA loggers.

SAGA Digital Data Logger Issues (continued)

Step 1.

Connect the temperature monitoring device to a computer that has access to your local network using the USB cable provided with the temperature monitoring device. Manually upload the temperature monitoring data onto the computer.

Step 2.

The data file will upload onto the computer in the form of a *.bin file*. Once you have located the *.bin* file on your computer, please manually upload this file to <https://upload.controlant.com/>. Manually uploading the data to this website allows the data from the temperature monitoring device to reach the Pfizer Control Tower which helps to ensure supply chain visibility.

Step 3.

Once the data is received at the Control Tower, a quality disposition report is created which documents quality considerations and identifies any suspected nonconforming items.

A full set of instructions and troubleshooting information can be found on the Pfizer website at [Receiving your single-use Controlant shipment - Pfizer](#)

Vaccine Management

Eric Norton, My Turn and Claudia Aguiluz, CDPH

Get Ready for My Turn Release 26!

Clinic Managers and Vaccine Administrators

New updates for My Turn Public and Clinic will launch May 9th. Stay tuned for more information about the release!



Release Highlights

- ✓ Post appointment communications will be updated to check administration date and time.
- ✓ Patient Name and DOB will be added on Manage Your Appointment page.
- ✓ Experience enhancements for Public Portal will occur.

My Turn Public

Release Highlights

- ✓ Email/Callback Fields will be added for the live chat feature.
- ✓ Use ENTER to Load Appointment Search Results.
- ✓ Use ENTER to Login.
- ✓ A rebooking option will be added.
- ✓ The "Consent Type" field will be added to the bulk upload functionality.
- ✓ 4-day grace period for birthdays for Moderna, Pfizer and Janssen.

My Turn Clinic

What's Next in myCAvax? - Release 25

Providers

New updates for Providers, LHDs, and MCEs launched April 28th.



Providers

Orders

- ✓ UI Updates to Multi-line Ordering occurred to update help text and add account name.
- ✓ Community vaccine order page layout is read-only.

Account

- ✓ Medical Staff now have a role of 'Medical Staff' instead of 'Other'.

Vaccine Marketplace

- ✓ The 'Assigned To' field for community users was moved and filters to only display LHD and CDPH users.

Other

- ✓ Improved experience for TPR Shipment incidents – email notification, new status reason, additional access.
- ✓ Chatter was enabled on the Storage Capacity Object.
- ✓ SDIR information was removed during Enrollment to support SDIR to CAIR2 merge.

What's Next in myCAvax? Release 25

Multi-Line Ordering Updates Providers

New Vaccine Order Request

1

Need help? Review the job aid(s) for [placing vaccine order requests](#), [COVID-19 product guide](#), [shipping cadence](#), [Reporting Inventory to VF](#) and [COVID Locating Health](#).

2

Step 1: Select Location, Provide Inventory and Doses Administered for Vaccine you Intend to Order

- Select the location account.
 - Review your Reported Inventory that is automatically pulled from the latest data in VaccineFinder every afternoon at 2pm PST
 - If the VaccineFinder inventory is incorrect, update your inventory on the [VaccineFinder](#) website and remember to report to VaccineFinder daily.
 - Enter your On-Hand Inventory and Doses Administered **only for the vaccine(s) you intend to order.**

* Account

Mickey Mouse Clubhouse

4

Reported Inventory (VaccineFinder)			On-hand inventory			Doses administered		Order size	
* Vaccine product	Quantity	Last updated	* Quantity	Lot number	Expiration / Beyond use date	* Quantity	Order increments	* Doses requested	
Pfizer Tris-sucrose (12 years - 100+ years) - 300/box - COVID-19 Vaccine	---	---	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	30 dose min 6 (under 300) 300 (over 300)	<input type="text" value="0"/>	Clear Row
Pfizer (5 years - 11 years) - 100/box - COVID-19 Vaccine	---	---	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	10 dose min 10 (under 100) 100 (over 100)	<input type="text" value="0"/>	Clear Row
Moderna (18 years - 100+ years) - 100/1 box of 10 - COVID-19 Vaccine	---	---	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	30 dose min 5 (under 100) 100 (over 100)	<input type="text" value="0"/>	Clear Row
Janssen (18 years - 100+ years) - 100/2 boxes of 50 - COVID-19 Vaccine	---	---	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	30 dose min 5 (under 100) 100 (over 100)	<input type="text" value="0"/>	Clear Row

The updated multi-line ordering screen includes:

1. Reordered job aids
2. Updated VaccineFinder import time (it's 2 pm PST)
3. Clarifying language next to trash can icon
4. Products displayed in reverse alphabetical order

What's Next in myCAvax? Release 25

Shipment Incident Email for Providers



Hello 123 Vaccine - Los Angeles,

Thank you for submitting a shipment incident report. A record has been created, with the reported information listed, below.

As a next step in the resolution of your shipment incident, please contact the appropriate redistributor (Shipper). For Small Orders redistributed by AmerisourceBergen (TPR) please email C19vaccineops@amerisourcebergen.com. You may include the Shipment Incident number listed below. A copy of this notification, and any attached files submitted as part of the report, have been shared with them to facilitate the resolution of the incident.

Incident Details:

Shipment Incident: S-0363

Provider Location: Hello 123 Vaccine - Los Angeles

Shipper: Third-Party Redistributor

Date Shipment Was Received: April 1, 2022

Product: Moderna (18 years - 100+ years) - 140/1 box of 10 - COVID-19 Vaccine

Lot Number: 123456

Incident Type: Broken

Number of Doses Impacted: 100

Tracking Number: 987654321

Incident Related To: Vaccine

Upon resolution of your incident, you will need to update your shipment incident in myCAvax to include the assigned report case number and any resolution.

If you have any questions about the shipment incident referenced above, please contact us via email at COVIDCallCenter@cdph.ca.gov



Thank you,
California COVID-19 Vaccination Program



All Shipment Incidents must be recorded in myCAvax. Please follow up with the redistributor on the Shipment Incident whether it is the TPR, or your LHJ.

When you record a new Shipment Incident in myCAvax, an email will be sent with next steps in the Shipment Incident process and information entered in the record.

Reminder:

If you record a shipment incident that involves California's Third-Party Redistributor, follow-up with AmerisourceBergen at the email provided!

The background of the slide is a festive, celebratory scene. It features several balloons in various colors: gold, dark blue, and white with gold polka dots. The balloons are scattered across the frame, some in the foreground and some in the background. Interspersed among the balloons are numerous small, golden streamers or confetti pieces, creating a bright and cheerful atmosphere. The overall color palette is dominated by gold, blue, and white.

VACCINEFINDER UPDATE!

Providers will start reporting vaccine inventory **weekly, by close of business on Fridays** starting May 1, 2022.

All other reporting provisions remain the same.

Waste Event Reminders

Providers



When waste occurs:

- Remove spoiled, expired, or wasted vaccines from the storage unit immediately.
- Do not return nonviable vaccines to the manufacturer or McKesson.
- Report nonviable doses in myCAvax before disposal.



To report a Waste Event, login to myCAvax and click Vaccine Inventory – > Waste to report spoiled, expired, or wasted vaccines before disposing of vaccines. Include product, lot number, and expiration date.



Reminder: Confirm all information is correct before submitting a report. Waste Events cannot be deleted under any circumstance.

Redistribution Transfer Changes

Providers

Review Transfer

Confirm details of receipt of the transfer.

Order Number	Product
00051129	Janssen (18 years - 100+ years) - 100/2 boxes of 50 - COVID-19 Vaccine
Lot Number	Transfer Type
A1234	Redistribution transfer
Number of Doses Transferred	Transfer Date
10	2022-04-21
*Doses Received?	Transfer Time
<input checked="" type="radio"/> Yes	07:00 AM
<input type="radio"/> No	
*Indicate if you are accepting or rejecting this shipment	New Beyond Use Date (If Applicable)
Accept	
*Were vaccines exposed to out-of-range temperature?	
<input type="radio"/> Yes	
<input checked="" type="radio"/> No	



Once you have submitted a Redistribution Transfer, you cannot make any edits to the transfer information. The receiver cannot edit the transfer information either. Please accurately fill out the Transfer record before submitting.

Reach out to the Provider Call Center covidcallcenter@cdph.ca.gov or (833) 502-1245 with any questions on Transfers.

APPENDIX

What's Next on myCAvax: Release 25 (04/28)

Order

- ✓ Approval Date is captured on Orders.
- ✓ UI Updates occurred to Multi-line Ordering to update help text and add account name.
- ✓ Community vaccine order page layout is now read-only.

Account

- ✓ Medical Staff now have a role of 'Medical Staff' instead of 'Other'.
- ✓ LHD and MCE Account layout has been altered to break out the current "Related" tab.

Vaccine Marketplace

- ✓ The 'Assigned To' field for community users was moved and now filters to only display LHD and CDPH users.

Other

- ✓ Improved experience for TPR Shipment incidents – email notification, new status reason, additional access.
- ✓ Visit Scheduled date on Site Visits is no longer be required.
- ✓ Chatter was enabled on Storage Capacity Object.
- ✓ SDIR information was removed during Enrollment to support SDIR to CAIR2 merge.

myCAvax – Known Issues - *Updated 4/22*

Known Issues

Vaccine Finder Data Not Updating on Your Order?

- ✓ We are currently investigating 'Most Recent Inventory Update' showing incorrectly for users who believe that they reported accurately. If you just recently updated 'Vaccine Finder', please wait at least 24-36 hours before the system can update accordingly. If you are still not seeing your expected result, please verify that the NDC code you are reporting under matches the NDC code for your order, minus the last two digits.



Workaround/Next Steps

- ✓ If after waiting 24-36 hours and confirming that the NDC code is correct, you are still not receiving the expected results, please contact the Provider Call Center

myCAvax Release Roadmap

Providers and LHDs/MCEs

RECENTLY DEPLOYED

April 7th (R24.0)

Order

- ✓ Opt Out of Ancillary Kit Help Text
- ✓ Doses Requested Minimum and Fulfillment Method Automation for Redistributor
- ✓ Make Order Doses Requested "Smart"
- ✓ TPRs will only have access to their own orders and Redistribution Orders
- ✓ Remove Intended Use
- ✓ Create Order on Internal screen allows LHDs to search by account or COVID ID

Account

- ✓ Reconfigure Related Lists on Account for CDPH
- ✓ Add Bounced Email field on Contact records

Community

- ✓ Dynamic Landing Pages for Providers
- ✓ IIS ID Address Static Text Updates
- ✓ Remove Rejected Applications for Providers

Waste Events

- ✓ Flag Waste Events with High '# Doses Wasted'

IN PROGRESS

April 28th (R25.0)

Order

- ✓ Capture Approval and Submission Dates on Orders
- ✓ UI Updates to Multi-line Ordering to update help text and add account name
- ✓ Community vaccine order page layout read-only and allowing providers to save a draft order on Page 1

Account

- ✓ Medical Staff will now have a role of 'Medical Staff' instead of 'Other'
- ✓ Account Tab Changes for LHD/MCEs, Help Desk Staff

Vaccine Marketplace

- ✓ Moving the 'Assigned To' field for community users and filtering to only display LHD and CDPH users

Other

- ✓ Improved experience for TPR Shipment incidents – email notification, new status reason, additional access
- ✓ Visit Scheduled date on Site Visits no longer be required
- ✓ Chatter enabled on Storage Capacity Object
- ✓ Removing SDIR information during Enrollment to support SDIR to CAIR2 merge

UPCOMING

May 19th (R26.0)

Orders

- ✓ Product Groupings and Colors on Multi-line Order screen
- ✓ Allow LHDs to easily move standard orders to small orders
- ✓ Mass Update Order Flows to Include or Exclude Orders
- ✓ Dynamically Filter Preferred Vaccine Temperature on Vaccine Order Review Page

Account

- ✓ Easily identify active contacts
- ✓ Allow Enrollment team to easily reject Location Applications

Community

- ✓ Training Page for Product and CDC Training

Site Visits

- ✓ Email Automation for Site Visits
- ✓ Addition of VFC Information on Site Visits
- ✓ Update Status of Site Visit based on Scheduled Date

Other

- ✓ Enable Quick Text in myCAvax
- ✓ Exclude Waste Events with a High '# of Doses Wasted' from VTrckS

My Turn Public Product Roadmap

RECENTLY DEPLOYED

April 6th (R25)

Release 25

- ✓ 2nd Booster dose
 - ✓ Pfizer and Moderna for 50+ patients and 18-49 immunocompromised patients (individual and group flow)
 - ✓ Pfizer Only for 12-17 immunocompromised residents (individual and group flow)
- ✓ Add a new "COVID + Flu" tag for combo clinics
- ★ ✓ Translation Audit for Public Portal
- ★ ✓ Data Templates Technical Review (enhancement to reduce release risk)
- ✓ Testing Public flows for Government Cloud Plus migration
- ✓ Analysis - Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability
- ✓ Experience enhancements:
 - ✓ Public site to support format customization for checkboxes
 - ✓ Enhanced Landing page
- ★ ✓ Create a Group Scheduling specific report

CURRENT

May 9th (R26)

Release 26

- ✓ Failure Point Notification – setting up monitoring tools throughout My Turn System to flag (potential) issues
- ★ ✓ FHIR Integration – redirect residents from vaccine.gov to My Turn
- ✓ Add Patient Name and DOB on Manage Your Appointment page
- ✓ Add Clinic Address on confirmation page for patient's reference
- ✓ Continued Analysis - Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability
- ✓ Update post appointment communications to check administration date and time
- ✓ Experience enhancements for Public Portal

UPCOMING

June 1st (R27)

Release 27

- ✓ Baby Moderna (if approved)
- ✓ Deactivate Flu vaccine from Public Portal
- ✓ Update error messaging for better user experience, and accessibility
- ✓ (Continued) Failure Point Notification – setting up monitoring tools throughout My Turn System to flag (potential) issues
- ✓ Continued Analysis - Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability
- ✓ Allow patients 4 days from their 5th birthday to book initial COVID appt

TBD (as approved):

- ✓ Baby Pfizer
- ✓ Baby Moderna
- ✓ Moderna 6 years to 11 years
- ✓ 5-11 Pfizer Booster

My Turn Clinic Product Roadmap

RECENTLY DEPLOYED

April 6th (R25)

Release 25

- ✓ SDIR Merge with CAIR2
- ✓ [Clinic Specific link] - Add an Expiration Date Column
- ✓ Self-Service Clinic Specific Link
 - ✓ Deactivation Functionality
- ✓ [Walk-In 5-11 Update] - Clinics without 5-11 Vaccine Supply/Inventory
- ★ ✓ Adding filters to the Clinic Tab
- ★ ✓ Automatically Set 'Pending Complete' appointments to 'Vaccinated'
- ✓ Live Chat Enhancements
 - ✓ Redesign Live Chat Button
 - ✓ Add "in Queue" Chat
 - ✓ Live Chat Identification Name Field/Form
 - ✓ Agree/Decline PII Statement
- ✓ Bulk Upload Hybrid Import
- ★ ✓ Adding Syncope as an Immediate Adverse Reaction
- ✓ Flu Add-on Tag Validation on Clinic
- ✓ Removal of Hybrid Profiles
- ✓ Use ENTER to Load IIS Search Results
- ✓ Pfizer & Moderna 2nd Booster Eligibility

CURRENT

May 9th (R26)

Release 26

- ✓ [Pfizer & Moderna 2nd Booster]
 - ✓ Add New Appointment
 - ✓ Single/Bulk Update
 - ✓ Bulk Upload/Inline
 - ✓ IIS Status Tab
- ✓ [POC] - Accounting for Clinic Appointments for Public Portal Availability (AWS)
- ✓ 4 Day Grace Periods for Pfizer, Moderna & J&J
- ✓ [Live Chat Enhancements] Email/Callback Fields
- ✓ Use ENTER to Load Appointment Search Results
- ✓ Use ENTER to Login
- ✓ New Link to the Walk-in and VA flow
- ✓ Bulk Upload Enhancements
 - ✓ Show History of the past 7 days
 - ✓ Update Scrollbar
- ✓ Add a Rebooking Option
 - ✓ Confirmation Page
 - ✓ SMS/Email confirmation
- ✓ Consent Type Enhancements
 - ✓ Bulk Upload "Consent Type" field

UPCOMING

(R 27)

Release 27

- ✓ Moderna 6m-6y Updates
- ✓ Pfizer 5-11 Booster Updates
- ✓ Flu Removal from My Turn
 - ✓ Walk-in Flow
 - ✓ Clinic Setup Flow
 - ✓ VA flow
 - ✓ Bulk Appointment Upload

TBD

Priorities

- ★ ★ ✓ **Pfizer three-dose vaccine rollout for 6 months to 4-year-old residents**
 - ✓ VA Flow Updates & EUA Links
 - ✓ Update to Dose Fields
 - ✓ Add Vaccine Supply & Inventory
 - ✓ Bulk Upload Appointment Template Update
 - ✓ Clinic Setup
- ✓ **Pfizer Booster 5-11 y/o**

Wrap-up

Leslie Amani, CDPH

Additional Support

Type of Support

Description

Updated 12.29.21



COVID-19 Provider Call Center

The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: covidcallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–6PM



Enrollment Support

For Provider enrollment support, please contact myCAvax Clinic Operations at

- Email: myCAvaxinfo@cdph.ca.gov



myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: myCAvax.HD@Accenture.com
- Phone: (833)-502-1245, option 3, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM-1PM

For training opportunities: <https://eziz.org/covid/education/>




My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): myturnonboarding@cdph.ca.gov

For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Accenture.com or (833) 502-1245, option 4: Monday through Friday 7AM–7PM, Saturday and Sunday 8AM–1PM.

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)

Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



Monitor What You See and Hear

Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, report it to rumors@cdph.ca.gov

[Contact](#)

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Thank you!



Monday:

My Turn myCAvax Office Hours

Next session: Monday, May 2, 12PM

Friday:

Provider Office Hours

Next session: Friday, May 6, 9AM

Thank you to Provider Office Hours' Planning Team: Leslie Amani, Rachel Jacobs, Hailey Ahmed, Blanca Corona.